iPSC, hESC Comparisons Study To Assess Therapeutic Potential

Both cell types are believed to share equal characteristics, abilities and potential to differentiate into nearly 220 different cell types. However, hESC are isolated from early human embryos and iPSC are derived from reprogrammed adult somatic cells, which makes them less controversial.

This newly published research in Stem Cells compared 25 hESC and 8 iPSC lines, which had similar abilities to differentiate into blood precursor cells, blood vessels, and eye cells. Comparing the characteristics of cells derived from iPSC and hESC, researchers found that blood and vascular derivatives from iPSC display abnormal molecular and/or cellular processes, compared to their corresponding hESC counterparts. The iPSC showed notably decreased growth and differentiation efficiency, sometimes 1000 fold less than hESC.

Additionally, iPSC showed higher tendency to senescence and signs of programmed cell death. Similarly, retinal pigment epithelium cells derived from iPSC began senescing in the first passage, indicating the observed phenomenon is not limited to blood and vascular lineages. A range of therapeutic cell types obtained from iPSC showed abnormal expansion and early aging.

Robert Lanza, chief scientific officer at ACT and senior author of the study, said: “Before clinical application, it will be necessary to determine the cause and extent of such abnormalities, and whether they also occur in stem cells generated using different reprogramming methods. Although there is excitement that iPSC can serve as an embryo-free source of stem cells, it would premature to abandon research using hESC until we fully understand what’s causing these problems.”